Lifemd Inc (LFMD)

$4.45 -0.09 (-1.98%)
Market Cap 219.57M
Revenue (ttm) 194.06M
Net Income (ttm) 14.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 122.29
Profit Margin 7.39%
Debt to Equity Ratio 0.00
Volume 830,300
Avg Vol 1,350,640
Day's Range N/A - N/A
Shares Out 48.36M
Stochastic %K 18%
Beta 2.03
Analysts Strong Sell
Price Target $9.88

Company Profile

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides vi...

Industry: Health Information Services
Sector: Healthcare
Phone: 866 351 5907
Website: lifemd.com
Address:
236 Fifth Avenue, Suite 400, New York, United States
MarioAndretti
MarioAndretti May. 15 at 2:01 AM
$LFMD Sell off tommrow as call options expire time to buy
0 · Reply
ClarissaLove
ClarissaLove May. 14 at 8:20 PM
$LFMD HIMS acquired more weight loss patients in 6 weeks than LFMD did in 2 years…and LFMD had a significant first mover advantage. As the market for weight loss drugs matures, little guys like LFMD will start dropping like flies. We already saw it with K Health $HIMS
3 · Reply
Alex1965
Alex1965 May. 14 at 4:02 PM
$LFMD Did anybody run the numbers if the guidance is maintained ??? Long LFMD
0 · Reply
Alex1965
Alex1965 May. 14 at 1:47 PM
$LFMD FWIW https://ir.lifemd.com/shareholder-letter.php Long LFMD
0 · Reply
MarioAndretti
MarioAndretti May. 13 at 8:51 PM
$LFMD up on the day unlike them fucktards at $HIMS
1 · Reply
Alex1965
Alex1965 May. 13 at 4:48 PM
$LFMD It was under $14 like a moth ago.
0 · Reply
Alex1965
Alex1965 May. 13 at 4:47 PM
$LFMD Maybe a good opportunity below $17.25. What do you say ??? https://seekingalpha.com/news/4592296-these-are-the-10-most-heavily-shorted-stocks-in-the-market-right-now?mailingid=45694398&messageid=2900&position=rta_news_toplink_analysis_popular_main_2_textlink&serial=45694398.13184&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=45694398.13184
0 · Reply
MarioAndretti
MarioAndretti May. 13 at 2:25 AM
$LFMD hope we hit 4 this is undervalued should be at 7-8.
0 · Reply
TaoistTrader
TaoistTrader May. 12 at 9:05 PM
$HIMS $LFMD ‼️⛔️⚠️ danger zone
0 · Reply
30DeltaSpy
30DeltaSpy May. 12 at 2:41 PM
$HIMS $LFMD $NVO NVO has 130% upside potential I am bullish on this one 1️⃣
0 · Reply
Latest News on LFMD
LifeMD reports Q1 EPS (20c), consensus (12c)

2026-05-07T00:47:06.000Z - 8 days ago

LifeMD reports Q1 EPS (20c), consensus (12c)

LifeMD sees Q2 revenue $47M-$50M, consensus $53.74M

2026-05-07T00:46:21.000Z - 8 days ago

LifeMD sees Q2 revenue $47M-$50M, consensus $53.74M

LifeMD backs FY26 revenue view $220M-$230M, consensus $223.59M

2026-05-07T00:45:57.000Z - 8 days ago

LifeMD backs FY26 revenue view $220M-$230M, consensus $223.59M

LifeMD Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 8 days ago

LifeMD Earnings Call Transcript: Q1 2026

LifeMD Reports First Quarter 2026 Results

May 6, 2026, 4:05 PM EDT - 8 days ago

LifeMD Reports First Quarter 2026 Results

LifeMD to Report First Quarter 2026 Financial Results on May 6

Apr 27, 2026, 8:00 AM EDT - 17 days ago

LifeMD to Report First Quarter 2026 Financial Results on May 6

LFMDP

LifeMD management to meet with BTIG

2026-04-24T17:05:27.000Z - 20 days ago

LifeMD management to meet with BTIG

LifeMD now offering Foundayo from Eli Lilly

2026-04-10T12:26:19.000Z - 4 weeks ago

LifeMD now offering Foundayo from Eli Lilly

LLY

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

Apr 10, 2026, 8:15 AM EDT - 4 weeks ago

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LFMDP

LifeMD announces launch of Wegovy subscription program

2026-03-31T14:25:15.000Z - 6 weeks ago

LifeMD announces launch of Wegovy subscription program

NVO

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Mar 31, 2026, 8:45 AM EDT - 6 weeks ago

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

LFMDP

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LFMDP

LifeMD management to meet virtually with B. Riley

2026-03-17T15:41:34.000Z - 2 months ago

LifeMD management to meet virtually with B. Riley

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

Mar 16, 2026, 8:00 AM EDT - 2 months ago

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

LifeMD upgraded to Outperform from Neutral at Mizuho

2026-03-16T08:40:05.000Z - 2 months ago

LifeMD upgraded to Outperform from Neutral at Mizuho

LifeMD price target raised to $10 from $8 at Freedom Capital

2026-03-12T14:11:07.000Z - 2 months ago

LifeMD price target raised to $10 from $8 at Freedom Capital

LifeMD price target raised to $10 from $9 at H.C. Wainwright

2026-03-11T10:15:39.000Z - 2 months ago

LifeMD price target raised to $10 from $9 at H.C. Wainwright

LifeMD Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 2 months ago

LifeMD Earnings Call Transcript: Q4 2025

LifeMD reports Q4 EPS 41c, consensus 3c

2026-03-09T20:21:55.000Z - 2 months ago

LifeMD reports Q4 EPS 41c, consensus 3c

LifeMD sees Q1 revenue $48M-$49M, consensus $45.61M

2026-03-09T20:21:26.000Z - 2 months ago

LifeMD sees Q1 revenue $48M-$49M, consensus $45.61M

LifeMD sees FY26 revenue $220M-$230M, consensus $222.64M

2026-03-09T20:20:41.000Z - 2 months ago

LifeMD sees FY26 revenue $220M-$230M, consensus $222.64M

LifeMD Reports Fourth Quarter and Full Year 2025 Results

Mar 9, 2026, 4:05 PM EDT - 2 months ago

LifeMD Reports Fourth Quarter and Full Year 2025 Results

LFMDP

LifeMD options imply 10.9% move in share price post-earnings

2026-03-09T18:05:08.000Z - 2 months ago

LifeMD options imply 10.9% move in share price post-earnings

LifeMD to Participate in Two Investor Conferences During March

Mar 3, 2026, 4:05 PM EST - 2 months ago

LifeMD to Participate in Two Investor Conferences During March

LFMDP

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

Feb 23, 2026, 8:00 AM EST - 2 months ago

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

LFMDP

LifeMD closes $50M revolving credit facility

2026-01-06T13:47:34.000Z - 4 months ago

LifeMD closes $50M revolving credit facility

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

Jan 6, 2026, 8:30 AM EST - 4 months ago

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

LFMDP

LifeMD expands collaboration with Novo Nordisk for Wegovy pill

2026-01-05T13:36:18.000Z - 4 months ago

LifeMD expands collaboration with Novo Nordisk for Wegovy pill

NVO

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

Jan 5, 2026, 8:05 AM EST - 4 months ago

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

LFMDP

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

Nov 24, 2025, 8:00 AM EST - 6 months ago

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

LifeMD price target lowered to $9 from $13 at H.C. Wainwright

2025-11-19T16:30:10.000Z - 6 months ago

LifeMD price target lowered to $9 from $13 at H.C. Wainwright

LifeMD price target lowered to $6 from $8 at Mizuho

2025-11-19T13:35:26.000Z - 6 months ago

LifeMD price target lowered to $6 from $8 at Mizuho

LifeMD Earnings Call Transcript: Q3 2025

Nov 17, 2025, 4:30 PM EST - 6 months ago

LifeMD Earnings Call Transcript: Q3 2025

LifeMD Reports Third Quarter 2025 Results

Nov 17, 2025, 4:05 PM EST - 6 months ago

LifeMD Reports Third Quarter 2025 Results

LFMDP

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

Nov 17, 2025, 8:00 AM EST - 6 months ago

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

LFMDP

LifeMD to Participate in the BTIG Digital Health Forum

Nov 10, 2025, 8:00 AM EST - 6 months ago

LifeMD to Participate in the BTIG Digital Health Forum

LFMDP

LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

Nov 5, 2025, 5:15 PM EST - 6 months ago

LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

LFMDP

LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform

Nov 4, 2025, 9:15 AM EST - 6 months ago

LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform

LFMDP

LifeMD to Report Third Quarter 2025 Financial Results on November 6

Oct 23, 2025, 8:00 AM EDT - 7 months ago

LifeMD to Report Third Quarter 2025 Financial Results on November 6

LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program

Oct 22, 2025, 8:00 AM EDT - 7 months ago

LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program

LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers

Sep 30, 2025, 8:14 AM EDT - 8 months ago

LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers

NVO

LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk

Sep 30, 2025, 8:00 AM EDT - 8 months ago

LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk

LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Sep 25, 2025, 4:06 PM EDT - 8 months ago

LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

LFMDP

MarioAndretti
MarioAndretti May. 15 at 2:01 AM
$LFMD Sell off tommrow as call options expire time to buy
0 · Reply
ClarissaLove
ClarissaLove May. 14 at 8:20 PM
$LFMD HIMS acquired more weight loss patients in 6 weeks than LFMD did in 2 years…and LFMD had a significant first mover advantage. As the market for weight loss drugs matures, little guys like LFMD will start dropping like flies. We already saw it with K Health $HIMS
3 · Reply
Alex1965
Alex1965 May. 14 at 4:02 PM
$LFMD Did anybody run the numbers if the guidance is maintained ??? Long LFMD
0 · Reply
Alex1965
Alex1965 May. 14 at 1:47 PM
$LFMD FWIW https://ir.lifemd.com/shareholder-letter.php Long LFMD
0 · Reply
MarioAndretti
MarioAndretti May. 13 at 8:51 PM
$LFMD up on the day unlike them fucktards at $HIMS
1 · Reply
Alex1965
Alex1965 May. 13 at 4:48 PM
$LFMD It was under $14 like a moth ago.
0 · Reply
Alex1965
Alex1965 May. 13 at 4:47 PM
$LFMD Maybe a good opportunity below $17.25. What do you say ??? https://seekingalpha.com/news/4592296-these-are-the-10-most-heavily-shorted-stocks-in-the-market-right-now?mailingid=45694398&messageid=2900&position=rta_news_toplink_analysis_popular_main_2_textlink&serial=45694398.13184&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=45694398.13184
0 · Reply
MarioAndretti
MarioAndretti May. 13 at 2:25 AM
$LFMD hope we hit 4 this is undervalued should be at 7-8.
0 · Reply
TaoistTrader
TaoistTrader May. 12 at 9:05 PM
$HIMS $LFMD ‼️⛔️⚠️ danger zone
0 · Reply
30DeltaSpy
30DeltaSpy May. 12 at 2:41 PM
$HIMS $LFMD $NVO NVO has 130% upside potential I am bullish on this one 1️⃣
0 · Reply
Floyd_Mayweather_JR
Floyd_Mayweather_JR May. 12 at 3:43 AM
$HIMS this will end up like $LFMD and $TDOC history doesn’t always repeat but it often rhymes
2 · Reply
Alex1965
Alex1965 May. 11 at 10:51 PM
$LFMD I guess HIMS is going down to the $15 - $17 range again. Maybe that will teach the HIMS’s Trolls to stay on their side of the fence. And a new opportunity for new LT investors.
0 · Reply
Leroy_Jankins
Leroy_Jankins May. 11 at 8:19 PM
$LFMD where’s the latest LifeMD “We are not just a GLP-1 company” talk on Alpha Wolf??
1 · Reply
TaoistTrader
TaoistTrader May. 11 at 8:18 PM
$LFMD danger zone after $HIMS crappy earnings. Below 4 this is down the tubes bye bye
0 · Reply
thejman1
thejman1 May. 9 at 8:48 PM
$LFMD company keeps rolling out new stuff and nothing is profitable. nothing innovative. ceo keeps talking about care is amazing and all the subcribers. this company has so many bad reviews. People sign up. realize it isnt worth it. get hit with some additional hidden fees and never come back. explains all the bad reviews. same thing with worksimpli and rexmd. company has nothing that makes it unique. they just keep diluting share holders to pay employees with created shares. and they accomplish nothing but losses. probably bankrupt in 2 years. and 20 to 30% dilution. this is what is shown year after year.
1 · Reply
Leroy_Jankins
Leroy_Jankins May. 9 at 10:16 AM
$LFMD i wish these guys would just come out and say “GLP-1s were just one peptide and are a $100BN a year opportunity. LifeMD is going to go full steam ahead on incorporating peptides into our treatment plans and will become the de facto source for people to learn about and receive peptide treatment options” Complete game changer. Higher risk but they need to be at the forefront of this generational pivot in treatment options, not playing catchup to HIMS/RO/AMZN
0 · Reply
TaoistTrader
TaoistTrader May. 8 at 11:13 AM
$LFMD seems like it’s recovering. Stays above 4.4 it could be fine; below 4 it’s back to no mans land. I truly believe they are sand bagging for new CFO. It wouldn’t be wise to come out full throttle after his first ER. Set em up for success
1 · Reply
MarioAndretti
MarioAndretti May. 8 at 1:08 AM
$HIMS heading to 8$ in 2-3 years seen this before one lawsuit and back down she goes. I’ve been here since Microsoft launched their IPO. You want to invest in a tested and tried company $LFMD their ya go. And that’s free bitch
2 · Reply
dogfisher
dogfisher May. 7 at 11:16 PM
$LFMD Justin is a COO at best, but definitely not a CEO
0 · Reply
Phil1973
Phil1973 May. 7 at 11:00 PM
$LFMD https://seekingalpha.com/news/4588376-amazon-to-offer-novo-ozempic-pill
0 · Reply
Leroy_Jankins
Leroy_Jankins May. 7 at 5:22 PM
$LFMD if the company has such great upside potential some of the employees would buy but they don’t buy, they only sell. It’s been a pattern of award SBC and then everyone sells. I wish it had as much upside as they want people to believe but if even they believed it they would buy
0 · Reply
ClarissaLove
ClarissaLove May. 7 at 5:05 PM
$HIMS $LFMD Nope. Keep dreaming.
0 · Reply